{
    "nct_id": "NCT03341806",
    "official_title": "Phase I Study of PD-L1 Inhibition With Avelumab and Laser Interstitial Thermal Therapy in Patients With Recurrent Glioblastoma",
    "inclusion_criteria": "* Patients must have histologically proven GBM from the initial resection.\n* Patients must have a life expectancy > 16 weeks. Patients must have a Karnofsky performance status of ≥ 60 or ECOG 0 - 2\n* Patient's requirement for dexamethasone should be ≤ 4mg daily or a stable dose at enrollment.\n* Patients must have adequate bone marrow, hepatic and renal function and hemoglobin and the test musts be performed within 14 days prior to study Day 1.\n* Highly effective contraception for both male and female subjects if the risk of conception exists.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history of autoimmune disorder except diabetes mellitus type 1, vitiligo or hypothyroidism only requiring hormone replacement\n* Patients who have received any other therapeutic investigational agent within 30 days of enrollment with the exception of the personalized MTA vaccine (NCT03223103) that can be continued throughout the study.\n* Patients who have received any other therapeutic investigational agent within 30 days of enrollment or prior\n* Prior placement of intracavitary BCNU-impregnated wafers (Gliadel).\n* Prior treatment with checkpoint inhibitors, CTL-4 antibody or other immunotherapy agents\n* Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment.\n* Prior organ transplantation, including allogeneic stem cell transplantation\n* Significant acute or chronic infections including, among others: HIV, AIDS, HBV\n* Pregnancy or lactation\n\nContact site for full inclusion/exclusion list.",
    "miscellaneous_criteria": ""
}